Back to today’s briefing

Story perspectives

Pfizer and Novo Nordisk Battle for Metsera with $10B Bid

11/7/2025

50 8

Summary

Story summary

Pfizer, Inc. and Novo Nordisk A/S are bidding for Metsera, an obesity biotechnology company with a promising pipeline.
Pfizer initially offered $4.9 billion, then raised its bid to $8.1 billion.
Novo Nordisk countered with a $10 billion offer, which Metsera deemed superior.
Pfizer has filed lawsuits against Novo Nordisk alleging anticompetitive behavior.

1 of 1

Story summary

Pfizer, Inc. and Novo Nordisk A/S are bidding for Metsera, an obesity biotechnology company with a promising pipeline.
Pfizer initially offered $4.9 billion, then raised its bid to $8.1 billion.
Novo Nordisk countered with a $10 billion offer, which Metsera deemed superior.
Pfizer has filed lawsuits against Novo Nordisk alleging anticompetitive behavior.